Spexis AG (XSWX:SPEX) Days Sales Outstanding : 0.00 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Days Sales Outstanding?

Spexis AG's average Accounts Receivable for the six months ended in Jun. 2023 was CHF0.00 Mil. Spexis AG's Revenue for the six months ended in Jun. 2023 was CHF0.00 Mil.

The historical rank and industry rank for Spexis AG's Days Sales Outstanding or its related term are showing as below:

During the past 10 years, Spexis AG's highest Days Sales Outstanding was 638.75. The lowest was 17.65. And the median was 64.55.

XSWX:SPEX's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.66
* Ranked among companies with meaningful Days Sales Outstanding only.

Spexis AG's Days Sales Outstanding stayed the same from Jun. 2022 (0.00) to Jun. 2023 (0.00).

Spexis AG Days Sales Outstanding Historical Data

The historical data trend for Spexis AG's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Days Sales Outstanding Chart

Spexis AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

17.65

310.25

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Sales Outstanding	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Spexis AG's Days Sales Outstanding

For the Biotechnology subindustry, Spexis AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spexis AG's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Spexis AG's Days Sales Outstanding falls into.

Spexis AG Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Spexis AG's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Spexis AG's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding (Q: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 2
=	0					/	0	*	365 / 2
=	N/A

Spexis AG (XSWX:SPEX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Spexis AG Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Spexis AG's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines